Business
Nutriband Inc. Receives Patent Protection from Australia, Russia and Mexico
ORLANDO, Fla., March 18, 2020 /PRNewswire/ -- Nutriband Inc. (OTCQB: NTRB), a Nevada corporation (the "Company") has received a notice of grant from patent
About this update from Nutriband Inc.
[{"type":"text","content":"ORLANDO, Fla., March 18, 2020 /PRNewswire/ -- Nutriband Inc. (OTCQB: NTRB), a Nevada corporation (the \"Company\") has received a notice of grant from patent offices in Australia and Russia and a notice of allowance from Mexico's patent office for the 'Abuse and Misuse Deterrent Transdermal Systems' patent application filed by its clinical subsidiary 4P Therapeutics \n\nThe patent underpins 4P Therapeutics' abuse deterrent fentanyl transdermal system, which uses taste aversion to addresses the primary routes of abuse for opioid based transdermal patches. \nAbout Nutriband Inc.\nThe Company is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is its abuse deterrent fentanyl transdermal system which the Company is developing to provide clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy combined with properties designed to help combat the opioid crisis by deterring the abuse and misuse of fentanyl patches.\nThe Company's website is www.nutriband.com and 4P's website is www.4PTherapeutics.com. Any material contained in or derived from the Company's or 4P's websites or any other website is not part of this press release.\nAbout Our Forward-Looking Statements\nCertain statements contained in this press release, including, without limitation, statements containing the words \"believes,\" \"anticipates,\" \"expects\" and words of similar import, constitute \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory ap...